A *novel* humanized mouse model to study human antigen-specific cutaneous T cell responses *in vivo*.

#### Short title: Skin-humanized mouse model

Maria M. Klicznik<sup>1</sup>, Ariane Benedetti<sup>1</sup>, Laura M. Gail<sup>1</sup>, Raimund Holly<sup>1</sup>, Martin Laimer<sup>2</sup>, Angelika Stoecklinger<sup>1</sup>, Andreas Sir<sup>3</sup>, Roland Reitsamer<sup>3</sup>, Michael D. Rosenblum<sup>4</sup>, Eva M. Murauer<sup>5</sup>, Iris K. Gratz<sup>1,5,6</sup>

<sup>1</sup> Department of Biosciences, University of Salzburg, Salzburg, Austria

<sup>2</sup> Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, Austria

<sup>3</sup>Breast Center University Hospital of the Paracelsus Medical University Salzburg, Austria

<sup>4</sup>Department of Dermatology, University of California, San Francisco CA 94143, USA.

<sup>5</sup>Division of Molecular Dermatology and EB House Austria, Department of Dermatology,

Paracelsus Medical University Salzburg, Austria

<sup>6</sup>Benaroya Research Institute, 1201 9th AVE, Seattle, WA 98101 USA

#### Abstract

Human skin contains a significant number of T cells that support tissue homeostasis and provide protective immunity. T cell function in human skin is difficult to study due to a lack of adequate *in vivo* models. In this study we used immunodeficient NOD-*scid IL2r* $\gamma^{null}$  (NSG) mice that carried *in vivo*-generated engineered skin (ES) and received adoptively transferred human peripheral blood mononuclear cells. ES were generated from keratinocytes and fibroblasts only and initially contained no skin-resident immune cells. This reductionist system allowed us to study T cell recruitment and function in non-inflamed and non-infected human skin. We found that functional human T cells specifically infiltrated the human skin tissue and responded to microbial antigen *in vivo*. Importantly, T cell maintenance and function was supported by the microenvironment of human skin. We have thus generated a novel mouse model with broad

utility in studies of human cutaneous antigen-specific T cell responses and the role of the skin microenvironment to skin immunity *in vivo*.

#### Introduction

As the body's outermost barrier, the skin represents a unique and complex immunological organ. As such, healthy human skin contains around twice the number of T cells found in the blood of which the majority are memory T cells (Bos et al. 1989; Clark et al. 2006) that support tissue homeostasis and ensure adequate response to pathogens (Di Meglio et al. 2011; Klicznik et al. 2018; Nestle et al. 2009). Although significant advances in understanding the role of the skin microenvironment on T cell function and memory development in murine skin have been made (Mackay et al. 2015; Mackay et al. 2013; Pan et al. 2017), the specific contribution of keratinocyte- and fibroblast-derived signals to cutaneous immunity in human skin remain poorly understood. T cell responses are strongly influenced by the surrounding tissue (Hu and Pasare 2013; McCully et al. 2012), and T cells at different barrier sites show distinct functional and metabolic properties (Kumar et al. 2017; Pan et al. 2017), therefore it is crucial to study cutaneous immunity within its physiological compartment in vivo. Due to fundamental structural differences between human and murine skin, as well as a lack of direct correspondence between human and murine immune cell populations (Di Meglio et al. 2011; Gudjonsson et al. 2007; Perlman 2016; Shay et al. 2013), direct translation from the murine cutaneous immune system can be difficult. This emphasizes the need for mouse models that faithfully replicate conditions found in human skin. Humanized mice, in which immunodeficient mice are adoptively transferred with human peripheral blood mononuclear cells (PBMC) and transplanted with human full thickness skin derived from either healthy donors or patients with skin diseases are currently used to study human skin immunology in vivo (Boyman et al. 2004; King et al. 2009; Watanabe et al. 2015). In these models the rejection of skin allografts and xenogenic graft versus host disease (GvHD) development can

be readily studied (Racki et al. 2010), but antigen-specific activation of T cells has been much harder to follow. Additionally, if obtained from adult donors full-thickness skin grafts contain resident immune cells (Clark et al. 2006; Racki et al. 2010; Sanchez Rodriguez et al. 2014; Watanabe et al. 2015), making it difficult to functionally analyze and manipulate discrete skin-tropic T cell populations.

We hypothesized that humanized mice reconstituted with simplified human skin consisting only of keratinocytes and fibroblasts would provide a reductionist system allowing us to study human T cell recruitment and function in human skin in absence of acute inflammation. To this end, we used NOD-*scid IL2ry<sup>null</sup>* (NSG) mice that were adoptively transferred with human PBMC and carried *in vivo*-generated engineered skin (ES). This model serves as a novel platform for studying human cutaneous antigen-specific T cell responses, and the contribution of the skin microenvironment to skin immunity *in vivo*. Additionally, we provide a method to stimulate robust antigen-specific memory responses of cutaneous T cells in this system.

#### Results

Human T cells specifically infiltrate human engineered skin in a xenograft mouse model. To follow human skin infiltration by autologous human immune cells, we generated engineered skin (ES) from human keratinocytes and fibroblasts isolated from healthy human skin and immortalized (Merkley et al. 2009). ES was generated as described before (Wang et al. 2000) and allowed to heal and differentiate for a minimum of 30 days (Fig.1a). H&E staining revealed that the ES displayed histological features of human and not murine skin. Additionally, organotypic proteins such as human type VII collagen at the basement membrane of the ES and human cytokeratin 5/6 within the correct epidermal layers of the ES confirmed correct differentiation and human origin (Fig.1b). In parallel, human PBMC from the skin donor were isolated and stored in liquid nitrogen until use (Fig.1a). After complete wound healing of the ES PBMC were adoptively transferred, thus creating a mouse model designated huPBMC-ES-NSG.

Engraftment of human CD45<sup>+</sup> cells was detectable after 14 days in the spleen and after 21 days in the ES (Fig. 1c-d). After a period of 18 - 34 days mean levels of human CD45<sup>+</sup> cells in spleen and ES were at >18% (Fig. 1e). The majority of human cells (>94%) in spleen and ES were CD3<sup>+</sup> T cells (Fig. 1f) and human CD3<sup>+</sup> cells preferentially infiltrated human ES not the adjacent murine skin (Fig. 1g). CD4<sup>+</sup> and CD8<sup>+</sup> as well as TCR $\gamma\delta^+$  T cells engrafted within the spleen and ES at levels comparable to human PBMC and skin (Fig. 1h-i). The ratios of CD4<sup>+</sup> and CD8<sup>+</sup> T cells engrafting in spleen and ES reflected the physiological levels found in human PBMC and skin, respectively (Table in Fig. 1j).

In previous studies development of xenogeneic graft versus host disease (xeno-GvHD) occurred around 5 weeks after adoptive transfer of  $10^7$  human PBMC into NSG mice (Ali et al. 2012; King et al. 2008). To delay the development of GvHD we reduced cell numbers to  $1.8 - 3x10^6$  /mouse. Additionally, we limited all experiments to 35 days, which was before onset of GvHD thus avoiding convoluting effects on our studies.

Taken together, these data illustrate that the human T cell compartment can be reconstituted in spleen and ES of the huPBMC-ES-NSG mouse. Next, we sought to determine whether the model was suitable to study human T cell function within human skin *in vivo*.

## Cutaneous and splenic T cells from huPBMC-ES-NSG maintain the functional profile of T cells found in human skin and blood

We assessed the function of splenic and skin T cells following *ex vivo* stimulation and intracellular cytokine staining. Production of the Th2, Th17 and Th22 cytokines IL-13, IL-17 and IL-22, respectively, were preserved in CD4<sup>+</sup> T cells isolated from the huPBMC-ES-NSG mouse when compared to T cells from human blood and skin(Fig. 2a-b; e-g). By contrast,

increased percentages of CD4<sup>+</sup> T cells isolated from the spleen and ES produced GM-CSF (Fig. 2c; h-i). Interestingly while IFN $\gamma^+$ CD4<sup>+</sup> cells were increased in the spleen when compared to PBMC, the proportion of IFN $\gamma$  producing CD4<sup>+</sup> cells within the ES was comparable to skin from healthy donors (Fig. 2i). In addition to conventional T cells, CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells engrafted within the spleen and ES (Fig. 2d; j). Analogous to the cytokine profiles of splenic and cutaneous CD4<sup>+</sup> T cells, we assessed the cytokine secretion of CD8<sup>+</sup> T cells isolated from spleen and ES (Fig. 3). The cytokine profiles of CD8<sup>+</sup> T cells in ES and spleen were comparable to healthy human skin and PBMC with the exception of GM-CSF, which was increased within the ES, similar to the CD4<sup>+</sup> T cell population.

#### Engrafted T cells share a skin-homing memory-like phenotype

Since CD4<sup>+</sup> T cells represent the majority of skin-homing and -resident T cells (Clark et al. 2006; Watanabe et al. 2015), we focused on the function of cutaneous CD4<sup>+</sup> T cells. Confirming previous studies of PBMC engraftment in NSG mice, we found that human CD4<sup>+</sup> T cells isolated from mice did not express markers of naïve T cells such as CCR7 and CD45RA despite being present in the ingoing PBMC population (Ali et al. 2012) (Fig. 4a). Additionally, around half of them expressed cutaneous leukocyte antigen (CLA), a glycan moiety that promotes skin-homing (Clark et al. 2006) (Fig. 4b). Taken together these data indicate that engrafted CD4<sup>+</sup> T cells show a skin-tropic, memory-like phenotype.

#### Cutaneous CD4<sup>+</sup>T cells are locally activated by microbial antigen

Skin CD4<sup>+</sup> T cells play a crucial role in controlling cutaneous microbes (Belkaid and Tamoutounour 2016). Their specific role in responses against the commensal fungus *Candida albicans* (Lagunes and Rello 2016) is underlined by the fact that primary and acquired immunodeficiencies that lead to the impairment of CD4<sup>+</sup> T cell immunity can cause pathogenic *C.albicans* infections (Gosselin et al. 2010; Klein et al. 1984; Lagunes and Rello 2016; Ling et al. 2015; Puel et al. 2011). Consistent with that, the human circulating T cell pool contains *C.albicans*-specific memory T cells (Acosta-Rodriguez et al. 2007; Hernández-Santos and Gaffen 2012).

We hypothesized that memory T cells specific for *C.albicans*, engraft in the ES and can mount a local antigen-specific T cell response upon encounter of microbial antigen. Therefore, we applied heat killed C.albicans (HKCA) to the ES in vivo. Injection of free HKCA failed to elicit a detectable expansion or proliferation in the spleen or ES of treated mice (Supp. Fig. 1a-b; not shown). This was likely due to poor engraftment of HLA-DR<sup>+</sup>CD3<sup>-</sup> antigen presenting cells (APC) within the NSG strain (King et al. 2009) (Supp. Fig. 1c-d). Since *C.albicans* specific T cell responses depend on the presence of HLA-DR<sup>+</sup> APC (Acosta-Rodriguez et al. 2007; Park et al. 2018) we pulsed autologous monocyte derived dendritic cells (moDC) with HKCA (HKCA/moDC) and injected these intradermally into the ES. LPS activated moDC (LPS/moDC) served as a control for non-specific activation of T cells by cytokines derived from activated APCs. Injections were repeated 3 times within 7 days and were followed by flow cytometry analysis of T cells isolated from the ES and spleen one week after the last injection (Fig. 5a). Whereas the proportion of human CD45<sup>+</sup> cells in the spleen remained unaffected irrespective of the treatment, a slight increase in the percentage of human CD45<sup>+</sup> cells could be detected in ES injected with HKCA/moDC compared to LPS/moDC injected ES (Fig. 5b). Additionally, an increased proportion of CD4+ T cells expressed the proliferation marker Ki67 and significantly upregulated CD25 upon injection of HKCA/moDC, indicating activation of CD4<sup>+</sup> T cells in response to the encountered antigen (Fig. 5c). Interestingly the increased proliferation and activation of CD4<sup>+</sup> T cells in response to antigen was locally restricted to the injected ES and absent in splenic T cells (Supp. Fig. 2a-b).

Together these data show that the huPBMC-ES-NSG model provides a tool to monitor antigen-specific T cell responses within human skin *in vivo*.

#### Antigen-specific T cell responses remain detectable in donor-mismatched skin tissue

So far, we used a completely matched system where ES, PBMC and moDC were from the same donor. However, access to skin that is matched to the PBMC, presents a limiting factor in studies of human immune responses. To broaden the model's applicability, we sought to determine whether antigen-specific T cell responses could still be detected in the skin when using donor-mismatched tissues. Therefore, we compared cutaneous CD4<sup>+</sup> T cell responses to HKCA in donor-matched and -mismatched ES. ES were generated from two different donors (donor A or B) designated ES-NSG-A and ES-NSG-B. After complete wound healing, both recipients received PBMC from donor A and were injected intradermally with matched LPS/moDC or HKCA/moDC (from donor A) (Fig. 5d).

Significantly higher proportions of CD4<sup>+</sup> T cells from ES injected with HKCA/moDC expressed HLA-DR compared to LPS/moDC injected ES, indicating recent antigen-specific activation (Holling et al. 2004; Ko 1979; Oshima and Eckels 1990) (Fig. 5e). Moreover, ES injected with HKCA/moDC contained an increased proportion of CD4<sup>+</sup> T cells secreting IL17 and TNF $\alpha$  compared to LPS/moDC (Fig. 5f-g). Importantly, IFN $\gamma^+$  (Fig. 5h) and HLA-DR<sup>+</sup> CD4<sup>+</sup> cell proportions (Fig. 5e) were not expanded in allogeneic skin compared to the autologous setting. Additionally, CD4:CD8 ratios remained unchanged between skin T cells from matched and mismatched HKCA/moDC injected ES (Fig. 5i). Splenic CD4<sup>+</sup> T cells showed high levels of activation irrespective of the injected moDC and no HKCA-specific cytokine production (Supp.Fig. 2c-f) and, splenic CD4<sup>+</sup>:CD8<sup>+</sup> T cell ratios were unaltered in response to the allogeneic ES (Supp.Fig. 2g), indicating the absence of a systemic response. Together, these data suggest that T cells were not activated by allogeneic keratinocytes or fibroblasts and that mismatched tissues still allow the study human antigen-specific cutaneous CD4<sup>+</sup> T cell responses in the huPBMC-ES-NSG model.

#### Human skin tissue promotes T cell maintenance and function

Based on the finding that human T cells preferentially infiltrated the human over the murine skin and T cells within the ES closely resembled T cells found in human skin (Fig. 1-3), we hypothesized, that human skin and ES provide similar signals to infiltrating T cells. Interestingly skin-derived chemokines, such as CCL2, CCL5, CXCL10 and CXCL12 (Fig. 6 a-d) and cytokines involved in T cell survival and maintenance, such as IL7 and IL15 were detectable at comparable levels in ES and normal human skin (Fig. 6 e,f). Based on these data, we hypothesized that the antigen-specific T cell response we detected was dependent on skin tissue-derived signals. To test this, we injected either the ES of huPBMC-ES-NSG or a defined area of murine skin on the back of huPBMC-NSG mice with autologous HKCA/moDC or LPS/moDC (Fig. 6g). Compared to ES treated with HKCA/moDC, significantly lower numbers of CD3<sup>+</sup> cells infiltrated the murine skin. Importantly their frequency remained unaltered upon injection of HKCA/moDC, indicating a lack of antigenspecific activation (Fig. 6h). This suggests that the C.albicans specific T cell response detected in the huPBMC-ES-NSG model is not only a memory re-call response that is elicited by T cell-APC interaction, but requires tissue derived signals to support full memory T cell function.

#### Discussion

The majority of T cells in healthy human skin are CD45RO memory T cells that ensure adequate protective immunity on this peripheral barrier site (Bos et al. 1989; Klicznik et al. 2018; Watanabe et al. 2015). Most of our understanding of the development and function of protective T cell immunity in the skin is based on research using animal models with limited direct translation to humans (Di Meglio et al. 2011; Gudjonsson et al. 2007; Schreiner and King 2018). Therefore skin-humanized mouse models present a powerful platform to study cutaneous immune processes in vivo. Existing models in which PBMC and skin are grafted have been most useful for studying inflammatory processes of the skin (Boyman et al. 2004; Issa et al. 2010; Racki et al. 2010; Watanabe et al. 2015) but studies of human cutaneous immunity in steady-state in vivo have been difficult to realize. Additionally, healthy human skin contains a variety of adaptive and innate immune cells that impact the outcome of any intervention and study (Di Meglio et al. 2011; Klicznik et al. 2018; Pasparakis et al. 2014). Studying distinct immune processes in the skin requires simple traceable models, in which specific components can be independently manipulated. In that respect, neonatal foreskin grafts that contain 45-fold less T cells than adult human skin have been used to reduce the impact of resident cells (Watanabe et al. 2015), but even this tissue already contains T cells (Schuster et al. 2012). Here we combined engineered skin (ES) (Wang et al. 2000) devoid of any resident leukocytes, and adoptive transfer of human PBMC into immunodeficient NSG mice to generate a humanized mouse model (huPBMC-ES-NSG) that allows for specific study of individual immune cell populations, as well as the impact of tissue-derived signals on immunological processes in the skin.

Importantly, the use of ES permits precise control over the cell populations that partake in a specific immune response and targeted manipulation of keratinocytes and fibroblasts using CRISPR/Cas9 will facilitate to study the influence of selected pathways and the effects of these alterations on cutaneous immunity *in vivo*.

Poor engraftment of APC can limit antigen-specific T cell responses *in vivo* (King et al. 2009), which can be partly overcome by injection of DC loaded with antigen (Harui et al. 2011). However, we have found that antigen-specific recall responses require the support of the micromilieu, such as tissue-derived IL15 and IL7 (Belarif et al. 2018; Wang et al. 2011) and CD4<sup>+</sup> T cells failed to respond to antigen presented in murine skin. Importantly, we found

that healthy human skin- and ES-derived signals were remarkably similar, especially chemokines and cytokines involved in T cell recruitment and activation, such as CCL2 (Carr et al. 1994), CCL5 (Kawai et al. 1999), CXCL10 (Fukui et al. 2013), CXCL12 (Nanki and Lipsky 2001) and T cell function and maintenance, like IL7 (Adachi et al. 2015; Belarif et al. 2018) and IL15 (Adachi et al. 2015; Wang et al. 2011). This indicates that the huPBMC-NSG-ES model enables us to study the contribution of tissue-derived cues on cutaneous T cell maintenance and function.

Interestingly, the antigen-specific response was detectable in both, an autologous and an allogeneic setting. Thus, access to matched tissue samples is not limiting the study of cutaneous T cell responses in these humanized mice.

By engineering human skin tissue, we created an environment that allows the study of cutaneous T cell responses in absence of inflammation or infection *in vivo*. Additionally, the model may serve as a platform to test novel therapeutic interventions to treat cutaneous inflammation, tumors or autoimmune diseases. Taken together, the huPBMC-ES-NSG model provides a highly versatile tool to study cutaneous T cell responses and study and manipulate tissue-derived signals that impact skin immunity.

#### **Material and Methods**

**Mice.** Animal studies were approved by the Austrian Federal Ministry of Science, Research and Economy. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from The Jackson Laboratory and bred and maintained in a specific pathogen-free facility in accordance with the guidelines of the Central Animal Facility of the University of Salzburg. Human specimens. Normal human skin was obtained from patients undergoing elective surgery, in which skin was discarded as a routine procedure. Blood and/or discarded healthy skin was donated upon written informed consent at the University Hospital Salzburg, Austria.

#### PBMC isolation for adoptive transfer into NSG recipients and flow cytometry.

Human PBMC were isolated from full blood using Ficoll-Hypaque (GE-Healthcare; GE17-1440-02) gradient separation. PBMC were frozen in FBS with 10% DMSO (Sigma-Aldrich; D2650), and before adoptive transfer thawed and rested overnight at 37°C and 5% CO<sub>2</sub> in RPMIc (RPMI 1640 (Gibco; 31870074) with 5% human serum (Sigma-Aldrich; H5667 or H4522), 1% penicillin/streptomycin (Sigma-Aldrich; P0781), 1% L-Glutamine (Gibco; A2916801), 1% NEAA (Gibco; 11140035), 1% Sodium-Pyruvate (Sigma-Aldrich; S8636) and 0.1% β-Mercaptoethanol (Gibco; 31350-010). Cells were washed and 1.8-3x10<sup>6</sup> PBMC/mouse intravenously injected. Murine neutrophils were depleted with mLy6G (Gr-1) antibody (BioXcell; BE0075) intraperitoneally every 5-7 days as described before (Racki et al. 2010).

Generation of engineered skin (ES). Human keratinocytes and fibroblasts were isolated from human skin and immortalized using human papilloma viral oncogenes E6/E7 HPV as previously described (Merkley et al. 2009). Cells were cultured in Epilife (Gibco, MEPICF500) or DMEM (Gibco; 11960-044) containing 2% L-Glutamine, 1% Pen/Strep, 10% FBS, respectively. Per mouse, 1-2x10<sup>6</sup> keratinocytes were mixed 1:1 with autologous fibroblasts in 400µl MEM (Gibco; 11380037) containing 1% FBS, 1% L-Glutamine and 1% NEAA for *in vivo* generation of engineered skin as described (Wang et al. 2000).

11

T cell isolation from skin tissues for flow cytometry. Healthy human skin and ES were digested as previously described (Sanchez Rodriguez et al. 2014). Approximately 1cm<sup>2</sup> of skin was digested overnight in 5%CO<sub>2</sub> at 37°C with 3ml of digestion mix containing 0.8mg/ml Collagenase Type 4 (Worthington; #LS004186) and 0.02mg/ml DNase (Sigma-Aldrich; DN25) in RPMIc. ES were digested in 1ml of digestion mix. Samples were filtered, washed and stained for flow cytometry or stimulated for intracellular cytokine staining. Approx. 3 cm<sup>2</sup> of shaved dorsal mouse skin were harvested and single cell suspensions prepared as described (Gratz et al. 2014) and stained for flow cytometry.

**Flow cytometry.** Cells were stained in PBS for surface markers. For detection of intracellular cytokine production, spleen and skin single cell suspensions and PBMC were stimulated with 50 ng/ml PMA (Sigma-Aldrich; P8139) and 1 μg/ml Ionomycin (Sigma-Aldrich; I06434) with 10 μg/ml Brefeldin A (Sigma-Aldrich; B6542) for 3.5 hrs. For permeabilization and fixation Cytofix/Cytoperm (BectonDickinson; RUO 554714) or Foxp3 staining kit (Invitrogen; 00-5523-00) were used. Data were acquired on LSR Fortessa (BD Biosciences) or Cytoflex LS (Beckman.Coulter) flow cytometers and analyzed using FlowJo software (Tree Star, Inc.) A detailed list of the used antibodies can be found in the Supplements.

**Histological staining of skin sections.** Normal human skin, ES and adjacent murine skin were frozen in TissueTek (Sakura; TTEK). 7 μm cryosections were stained with Hemalum solution acid (Carl Rorth; T865.1) and Eosin Y aqueous solution (Sigma, 201192A). Human type VII collagen was stained by immunofluorescence using anti-human type VII collagen antibody and goat anti-rabbit A488 as secondary antibody,

12

ProLong<sup>™</sup> Gold Antifade Mountant with DAPI, (Invitrogen; P36931) was used for nuclear staining and mounting. For immunohistochemistry paraffin-embedded normal human skin and ES was stained for human Cytokeratin 5/6 according to the manufacturer's protocol using a Ventana BenchMark Series automated slide stainer with ultraView Universal DAB Detection kit (Roche, 760-500).

#### Generation of monocyte derived dendritic cells (moDC)

moDC were generated from frozen PBMC similar to what has been described previously (Sallusto and Lanzavecchia 1994). Briefly, PBMC were thawed and monocytes adhered for 75 min at 37 °C and 5% CO<sub>2</sub> in DC medium (RPMI 1640: 10% FBS, 2 mM L-Glutamine, 100 U/ml penicillin/streptomycin, 50 μM β-mercaptoethanol). After washing, adherent monocytes were cultured in DC medium supplemented with 50 ng/ml GM-CSF (ImmunoTools; 11343127) and 50 ng/ml IL-4 (ImmunoTools; 11340047) for 7 days to generate immature DC. After 6 days, cells were harvested and re-plated in DC medium without cytokines. For activation, moDCs were cultured for 9-13 hrs with 5ng/ml LPS (Sigma-Aldrich; L2880) or 10<sup>6</sup> cells/ml heat killed *Candida albicans* (eubio; tlrl-hkca). 1.8-3x10<sup>4</sup> moDC/mouse were intradermally injected in 50μl PBS/mouse.

#### ProcartaPlex<sup>™</sup> immunoassays from human skin and engineered skin

Human skin or ES from huPBMC-ES-NSG mice were stored at -70°C until use. Skin was taken up in PBS with Protease Inhibitor Cocktail (1:100) (Sigma-Aldrich; P8340) at 1ml/50mg skin, homogenized and filtered through 0.22µm SpinX columns. Suspensions were stored at -70°C until use. ProcartaPlex immunoassay was performed according to the manufacturer's protocol and measured using Luminex Magpix® system.

**Statistical analysis.** Statistical significance was calculated with Prism 7.0 software (GraphPad) by one-way ANOVA with Tukey's multiple comparisons test, or by un-paired student's t-test as indicated. Error bars indicate mean +/- standard deviation.

#### **Conflict of Interest.**

The authors declare no conflict of interest.

#### Acknowledgements.

We especially thank all human subjects for blood and skin donation and the nurses at the Breast Center University Hospital of the Paracelsus Medical University Salzburg, Austria. We thank Dr. Stefan Hainzl, EB House Austria, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, Austria, for the immortalization of primary human keratinocytes and fibroblasts. We thank Monika Prinz from the Department of Dermatology at the University Hospital of the Paracelsus Medical University Salzburg, Austria for help with the IHC staining and Peter Steinbacher from the Department of Biosciences at the University of Salzburg, Austria, for support with microscopy. This work was supported by the Focus Program "ACBN" of the University of Salzburg, Austria, by a grant from the Dystrophic Epidermolysis Bullosa Research Association (DEBRA) International and DEBRA Austria, and NIH grant R01AI127726. MMK is part of the PhD program Immunity in Cancer and Allergy, funded by the Austrian Science Fund (FWF, grant W 1213) and was recipient of a DOC Fellowship of the Austrian Academy of Sciences.

#### Author Contributions.

IGK, EMM, MDR and MMK conceptualized the study, MMK, EMM and IGK designed the experiments; MMK, AB, LMG and RH acquired the data; ML performed IHC staining, AS, RR, and A.Sir acquired human samples; MMK performed data analysis, MMK and IGK

14

interpreted the data and wrote the manuscript. All authors reviewed the final version of the

manuscript. IKG and EMM supervised the project.

#### References

- Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 2007;8(6):639–46
- Adachi T, Kobayashi T, Sugihara E, Yamada T, Ikuta K, Pittaluga S, et al. Hair folliclederived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma. Nat. Med. 2015;21(11):1272–9
- Ali N, Flutter B, Sanchez Rodriguez R, Sharif-Paghaleh E, Barber LD, Lombardi G, et al. Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype. PLoS ONE. 2012;7(8) Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429415/
- Belarif L, Mary C, Jacquemont L, Mai HL, Danger R, Hervouet J, et al. IL-7 receptor
  blockade blunts antigen-specific memory T cell responses and chronic inflammation
  in primates. Nat. Commun. 2018;9 Available from:
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203796/
- Belkaid Y, Tamoutounour S. The influence of skin microorganisms on cutaneous immunity. Nat. Rev. Immunol. 2016;16(6):353–66
- Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch. Dermatol. Res. 1989;281(1):24–30
- Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-α. J. Exp. Med. 2004;199(5):731–6

- Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. U. S. A. 1994;91(9):3652–6
- Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K-I, Dowgiert RK, et al. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. Baltim. Md 1950. 2006;176(7):4431–9
- Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity. 2011;35(6):857–69
- Fukui A, Ohta K, Nishi H, Shigeishi H, Tobiume K, Takechi M, et al. Interleukin-8 and CXCL10 expression in oral keratinocytes and fibroblasts via Toll-like receptors. Microbiol. Immunol. 2013;57(3):198–206
- Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, Fonseca S, et al. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J. Immunol. Baltim. Md 1950. 2010;184(3):1604–16
- Gratz IK, Rosenblum MD, Maurano MM, Paw JS, Truong H-A, Marshak-Rothstein A, et al. Cutting edge: Self-antigen controls the balance between effector and regulatory T cells in peripheral tissues. J. Immunol. Baltim. Md 1950. 2014;192(4):1351–5
- Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT. Mouse models of psoriasis. J. Invest. Dermatol. 2007;127(6):1292–308
- Harui A, Kiertscher SM, Roth MD. Reconstitution of huPBL-NSG Mice with Donor-Matched Dendritic Cells Enables Antigen-Specific T-cell Activation. J. Neuroimmune Pharmacol. 2011;6(1):148–57
- Hernández-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe. 2012;11(5):425–35

- Holling TM, Schooten E, van Den Elsen PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum. Immunol. 2004;65(4):282–90
- Hu W, Pasare C. Location, location, location: tissue-specific regulation of immune responses. J. Leukoc. Biol. 2013;94(3):409–21
- Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation. 2010;90(12):1321–7
- Kawai T, Seki M, Hiromatsu K, Eastcott JW, Watts GF, Sugai M, et al. Selective diapedesis of Th1 cells induced by endothelial cell RANTES. J. Immunol. Baltim. Md 1950. 1999;163(6):3269–78
- King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin. Exp. Immunol. 2009;157(1):104–18
- King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, et al. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin. Immunol. Orlando Fla. 2008;126(3):303–14
- Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in highrisk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 1984;311(6):354–8
- Klicznik MM, Szenes-Nagy AB, Campbell DJ, Gratz IK. Taking the lead how keratinocytes orchestrate skin T cell immunity. Immunol. Lett. 2018;200:43–51

- Ko HS. Ia determinants on stimulated human T lymphocytes. Occurrence on mitogenand antigen-activated T cells. J. Exp. Med. 1979;150(2):246–55
- Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep. 2017;20(12):2921–34
- Lagunes L, Rello J. Invasive candidiasis: from mycobiome to infection, therapy, and prevention. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2016;35(8):1221–6
- Ling Y, Cypowyj S, Aytekin C, Galicchio M, Camcioglu Y, Nepesov S, et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 2015;212(5):619–31
- Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon M-L, et al. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat. Immunol. 2013;14(12):1294–301
- Mackay LK, Wynne-Jones E, Freestone D, Pellicci DG, Mielke LA, Newman DM, et al. Tbox Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate. Immunity. 2015;43(6):1101–11
- McCully ML, Ladell K, Hakobyan S, Mansel RE, Price DA, Moser B. Epidermis instructs skin homing receptor expression in human T cells. Blood. 2012;120(23):4591–8
- Merkley MA, Hildebrandt E, Podolsky RH, Arnouk H, Ferris DG, Dynan WS, et al. Largescale analysis of protein expression changes in human keratinocytes immortalized by human papilloma virus type 16 E6 and E7 oncogenes. Proteome Sci. 2009;7:29
- Nanki T, Lipsky PE. Stimulation of T-Cell Activation by CXCL12/Stromal Cell Derived Factor-1 Involves a G-Protein Mediated Signaling Pathway. Cell. Immunol. 2001;214(2):145–54

- Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 2009;9(10):679–91
- Oshima S, Eckels DD. Selective signal transduction through the CD3 or CD2 complex is required for class II MHC expression by human T cells. J. Immunol. Baltim. Md 1950. 1990;145(12):4018–25
- Pan Y, Tian T, Park CO, Lofftus SY, Mei S, Liu X, et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature. 2017;543(7644):252–6
- Park CO, Fu X, Jiang X, Pan Y, Teague JE, Collins N, et al. Staged development of long-lived T-cell receptor αβ TH17 resident memory T-cell population to Candida albicans after skin infection. J. Allergy Clin. Immunol. 2018;142(2):647–62
- Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 2014;14(5):289–301
- Perlman RL. Mouse models of human disease. Evol. Med. Public Health. 2016;2016(1):170–6
- Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8
- Racki WJ, Covassin L, Brehm M, Pino S, Ignotz R, Dunn R, et al. NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection. Transplantation. 2010;89(5):527–36
- Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994;179(4):1109–18

- Sanchez Rodriguez R, Pauli ML, Neuhaus IM, Yu SS, Arron ST, Harris HW, et al. Memory regulatory T cells reside in human skin. J. Clin. Invest. 2014;124(3):1027–36
- Schreiner D, King CG. CD4+ Memory T Cells at Home in the Tissue: Mechanisms for Health and Disease. Front. Immunol. 2018;9 Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2018.02394/full

Schuster C, Vaculik C, Prior M, Fiala C, Mildner M, Eppel W, et al. Phenotypic characterization of leukocytes in prenatal human dermis. J. Invest. Dermatol. 2012;132(11):2581–92

- Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T, et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc. Natl. Acad. Sci. 2013;110(8):2946–51
- Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood. 2011;117(6):1888–98
- Wang CK, Nelson CF, Brinkman AM, Miller AC, Hoeffler WK. Spontaneous cell sorting of fibroblasts and keratinocytes creates an organotypic human skin equivalent. J. Invest. Dermatol. 2000;114(4):674–80
- Watanabe R, Gehad A, Yang C, Campbell L, Teague JE, Schlapbach C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci. Transl. Med. 2015;7(279):279ra39

#### **Figure Legends**

Figure 1: Engineered skin resembles human skin and is preferentially infiltrated by human T cells upon adoptive PBMC transfer. (a) Schematic of the huPBMC-ES-NSG model. (b) H&E staining and immunofluorescence staining of human type VII collagen in human skin, ES and murine skin, as indicated (upper two panels) as well as immunohistochemical staining of human Cytokeratin 5/6 in human skin and ES (lower panel). White bar = 100µm (c-g) Single cell suspensions of spleen and ES of huPBMC-ES-NSG mice were analyzed by flow cytometry. Each data point represents an individual human donor or experimental mouse. Circles represent data collected from huPBMC-ES-NSG mice using tissue of donor WT85 and squares donor WT70. The different fillings of the symbols indicate independent experiments. (c) Representative flow cytometry analysis and (d) graphical summary of proportion of human CD45<sup>+</sup> cell as % of live cells in the lymphocyte gate in spleen and ES at indicated time points after adoptive transfer of 2.5x10<sup>6</sup> PBMC. (e) Graphical summary of proportion of CD45<sup>+</sup> cells of live cells in spleen and ES 18-34 days after PBMC transfer. n=3-6/experiment; cumulative data of 5 independent experiments. (f) Graphical summary of the proportion of CD3<sup>+</sup> cells of live CD45<sup>+</sup> cells (g) Representative flow cytometry analysis and graphical summary of CD3<sup>+</sup> percentages in ES and adjacent murine skin gated on live lymphocytes. n=3-6/experiment; cumulative data of 3 independent experiments. Significance determined by paired student's t test; mean +/- SD. (h) Representative plots and graphical summary of TCR $\gamma\delta^+$  and CD3<sup>+</sup> cells of live CD45<sup>+</sup> in indicated tissues. (i) Representative flow cytometry plots of CD4<sup>+</sup> and CD8<sup>+</sup> of CD3<sup>+</sup>CD45<sup>+</sup> live gated cells (i) Summary of CD4 and CD8 expressing cells in human PBMC and skin and spleen and ES, gated on live CD3+CD45+ lymphocytes. n=3-6/experiment; Combined data of 6 independent experiments.

22

### Figure 2: Human CD4<sup>+</sup> T cells maintain their functional cytokine profile in spleen and ES

(**a-c**) Single cell suspensions of blood and skin of healthy donors and spleen and ES of huPBMC-ES-NSG mice were stimulated *ex vivo* with PMA/ionomycin and intracellular cytokine production was analyzed by flow cytometry. Representative analysis of IL17, IL22, IL13, GM-CSF and IFN $\gamma$  % of CD4<sup>+</sup> cells as indicated and (**d**) CD25 and Foxp3 expression by gated CD4<sup>+</sup>CD3<sup>+</sup>CD45<sup>+</sup> live leukocytes. (**e-j**) Graphical summary of the expression of the indicated markers by T cells from blood and skin of healthy donors and spleen and ES of huPBMC-ES-NSG mice by gated CD4<sup>+</sup>CD3<sup>+</sup>CD45<sup>+</sup> live leukocytes. n=3-6/experiment; cumulative data of 2-5 independent experiments as indicated by the symbol fillings.

## Figure 3: Human CD8<sup>+</sup> T cells maintain their functional cytokine profile in spleen and ES

(**a-e**) Graphical summary of flow cytometry analysis of IL17, IL22, IL13, GM-CSF and IFNγ producing CD8+CD3+CD45+ gated live leukocytes from blood and skin of healthy donors and spleen and ES of huPBMC-ES-NSG mice as indicated upon *ex vivo* stimulation with PMA/Ionomycin and intracellular staining. n=3-6/ experiment; combined data of independent 1-4 experiments.

# Figure 4: Skin and spleen infiltrating CD4+ T cells show skin-homing memory phenotype

Representative flow cytometry analysis of (**a**) CCR7 and CD45RA expression, and (**b**) CLA and CD45RA expression by gated CD4+CD3+CD45+ live leukocytes from blood and skin of healthy donors, spleen and ES of huPBMC-ES-NSG mice and graphical summary of the proportions of indicated cells by gated CD4+CD3+CD45+ live leukocytes. n=5-6/experiment; cumulative data of 2 independent experiments.

#### Figure 5: Cutaneous CD4+ T Cells are activated by local APCs and remain

responsive in allogeneic environment. (a) Schematic outline of the experiment. (b) Graphical summary of the proportion of CD45<sup>+</sup> cells among live cells in the lymphocyte gate in indicated organs of huPBMC-ES-NSG mice that received either LPS/moDC injections or HKCA/moDC injections into the ES. (c) Graphical analysis of the proportion of Ki67<sup>+</sup> proliferating cells and CD25<sup>+</sup> cells by gated CD4<sup>+</sup>CD3<sup>+</sup>CD45<sup>+</sup> live leukocytes from LPS/moDC or HKCA/moDC treated ES. n=2-7/experiment, cumulative data of 2-5 independent experiments. Statistical significance determined by 2-tailed unpaired student's t test; mean +/- SD. (d) Schematic: NSG mice bearing fully healed ES of one of two different skin donors (A and B) were adoptively transferred with either skin donormatched PBMC or skin donor-mismatched PBMC. Intradermal injections of donor A derived LPS/moDC or HKCA/moDC were performed as depicted. Single cell suspensions of ES and spleen were analyzed by flow cytometry after *ex vivo* stimulation with PMA/Ionomycin and intracellular staining. (e-h) Graphical summary of the proportion of skin CD4<sup>+</sup> T cells expressing the indicated markers following intradermal encounter of LPS/moDC (LPS) or HKCA/moDC (HKCA). Red data points represent CD4+ T cells isolated out of mismatched ES. Statistical significance determined by ANOVA and Tuckey's test for multiple comparison; mean +/-SD. (i) Graphical summary of the ratio between CD4<sup>+</sup> and CD8<sup>+</sup> T cells of isolated skin T cells gated by CD3<sup>+</sup>CD45<sup>+</sup> live leukocytes.

## Figure 6: Human skin and ES provide signals that support cutaneous T cell function

Cytokine and chemokine expression within tissues was determined by bead-based multicomponent analysis of ES from huPBMC-ES-NSG and 3 different healthy human skin donors. (**a-f**) Amount of the indicated chemokines or cytokines per mg skin. (**g**) huPBMC-NSG mice received intradermal injections of LPS/moDC or HKCA/moDC into a defined patch of murine skin on the back of the mouse or into ES of huPBMC-ES-NSG mice. Single cell suspensions of injected murine skin regions were analyzed by flow cytometry 7 days after last i.d. injection as indicated. **h**) Graphical summary of the proportion of CD3<sup>+</sup> T cells isolated from LPS/moDC (LPS) and HKCA/moDC (HKCA) injected murine skin and T cells isolated from the ES treated with HKCA/moDC (HKCA). Statistical significance determined by ANOVA and Tukey's test for multiple comparison; mean +/-SD

#### **Supplemantary Figures**

# Supp.Fig.1: Human antigen-presenting cells do not engraft well in huPBMC-ES-NSG model. (a) Experimental procedure of the injection of 5x10<sup>4</sup> free HKCA cells into the ES. Single cell suspensions of indicated organs were analyzed by flow cytometry. (b) Graphical summary of human CD45<sup>+</sup> cell proportions of live leukocytes in spleen and ES of mice that were left untreated (untrtd), injected with PBS or HKCA. (c) Representative flow cytometry analysis of CD3<sup>-</sup>HLA-DR<sup>+</sup> cells in human PBMC, skin and spleen and ES of huPBMC-ES-NSG and (d) graphical summary gated on live CD45<sup>+</sup> cells.

#### Supp.Fig.2: Splenic T cell are not activated by HKCA presented in the ES. (a-f)

Graphical summary of the expression of indicated markers by CD4<sup>+</sup> T cells of CD3<sup>+</sup>CD45<sup>+</sup> live leukocytes isolated from the spleen of huPBMC-ES-NSG mice after intradermal injection of LPS/moDC (LPS) or HKCA/moDC (HKCA) upon *ex vivo* stimulation with PMA/ionomycin and intracellular cytokine staining. (**g**) Ratio of CD4<sup>+</sup> to CD8<sup>+</sup> cells in spleens of huPBMC-ES-NSG mice, gated on CD3<sup>+</sup>CD45<sup>+</sup> live leukocytes.




Figure 1: Engineered skin resembles human skin and is preferentially infiltrated by human T cells upon adoptive PBMC transfer






Figure 2: Human CD4<sup>+</sup> T cells maintain their functional cytokine profile in spleen and ES











Figure 5: Cutaneous CD4<sup>+</sup> T Cells are activated by local APCs and remain responsive in allogeneic environment.







Supp.Fig.2: Splenic T cell are not activated by HKCA presented in the ES.

#### Table S1: Detailed list of antibodies and reagents

Tissue preparation		
Reagent	Company	Catalog number
Collagenase Type 4	Worthington	LS004186
DNAse	Sigma-Aldrich	DN25
RPMI 1640	Gibco	31870074
human serum	Sigma-Aldrich	H5667/H4522
Penicillin/streptavidin	Sigma-Aldrich	P0781 A2916801
L-Glutamine NEAA	Gibco Gibco	11140035
Sodium-Pyruvat	Sigma-Aldrich	S8636
β-Mercaptoethanol	Gibco	31350-010
PBS	Gibco	14190169
Ficoll Paque Plus	GE-Healthcare	GE17-1440-02
Protease Inhibitor Cocktail	Sigma-Aldrich	P8340
Cellular activation		
Reagent	Company	Catalog number
Brefeldin A	Sigma-Aldrich	B6542
Cytofix/Cytoperm kit	BD	RUO 554714
Foxp3 / Transcription Factor Staining Buffer Set lonomycin	Invitrogen Sigma-Aldrich	00-5523-00 106434
PMA	Sigma-Aldrich	P8139
Recombinant human IL2	Immunotools	11340023
Recombinant human IL4	Immunotools	11340047
Recombinant human GM-CSF	Immunotools	11343127
Purified NA/LE Mouse anti-human CD28 (CD28.2)	BD	555725
Functional Grade, CD3 monoclonal Antibody (OKT3)	eBioscience	16-0037-85
Cytokine/Chemokine/Growth Factor 45-Plex Human ProcartaPlex™	Invitrogen	EPX-450-12171-901
Skin cell culture and transplantation		
Reagent	Company	Catalog number
Epilife	Gibco	MEPICF500
DMEM MEM	Gibco Gibco	11960-044 11380037
	Gibco	
TrypLE express Primocin	invitrogen	12604021 ant-pm-1
X-VIVO 15	Lonza	881028
	Lonza	001020
Tissue preparation from mice Reagent	Company	Catalog number
BD Pharm Lyse	BD	555899
Collagenase from Clostridium histolyticum	Sigma-Aldrich	C9407
Hyaluronidase	Sigma-Aldrich	H3506
Histology		
Reagent	Company	Catalog number
Reagent Cell Conditioning 1 (CC1)	Roche	950-124
Reagent Cell Conditioning 1 (CC1) Eosin Y aqueous solution	Roche Sigma	950-124 HT110232
Reagent Cell Conditioning 1 (CC1) Eosin Y aqueous solution Hemalum solution acid acc. to Mayer	Roche Sigma Carl Rorth	950-124 HT110232 T865.1
Reagent Cell Conditioning 1 (CC1) Eosin Y aqueous solution Hemalum solution acid acc. to Mayer Human Cytokeratin 5/6 (D5/16B4)	Roche Sigma Carl Rorth Roche	950-124 HT110232 T865.1 790-4554
Reagent Cell Conditioning 1 (CC1) Eosin Y aqueous solution Hemalum solution acid acc. to Mayer Human Cytokeratin 5/6 (D5/16B4) ProLong ™ Gold Antifade Mountant with DAPI	Roche Sigma Carl Rorth Roche Invitrogen	950-124 HT110232 T865.1 790-4554 P36931
Reagent Cell Conditioning 1 (CC1) Eosin Y aqueous solution Hemalum solution acid acc. to Mayer Human Cytokeratin 5/6 (D5/16B4)	Roche Sigma Carl Rorth Roche	950-124 HT110232 T865.1 790-4554
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound	Roche Sigma Carl Rorth Roche Invitrogen Sakura	950-124 HT110232 T865.1 790-4554 P36931 TTEK
Reagent Cell Conditioning 1 (CC1) Eosin Y aqueous solution Hemalum solution acid acc. to Mayer Human Cytokeratin 5/6 (D5/16B4) ProLong™ Gold Antifade Mountant with DAPI TissueTek O.C.T. Compound ultraView Universal DAB Detection kit Antibodies	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Company	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 Catalog number
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit    Antibodies Reagent CLA FITC (HECA-452)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche <b>Company</b> Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Company	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 Catalog number
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA FITC (HECA-452)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche <b>Company</b> Biolegend BD	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA FITC (HECA-452)         CD1a FITC (HI149)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD BioLegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CD1a FITC (HI149)         CD3 PerCP-Cy5.5 (OKT3)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche <b>Company</b> Biolegend BD Biolegend eBioscience	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA FITC (HI49)         CD3 PerCP-Cy5.5 (OKT3)         CD3 bV405 (SK7)         CD3 PE (HIT3a)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche <b>Company</b> Biolegend BD BioLegend eBioscience BioLegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA bv605 (HECA-452)         CD1a FITC (H1149)         CD3 PerCP-Cy5.5 (OKT3)         CD3 bv421 (UCHT1)         CD3 bv605 (SK7)         CD3 PE (HIT3a)         CD3 PE-Cy5.5 (UCHT1)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend BD Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong ™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CD1a FITC (HIC49)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PE (UCHT1)         CD3 PE (HIT3a)         CD3 PE (HIT3a)         CD3 PE (APA-T4)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend BD Biolegend BD Biolegend BD Biolegend BD	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA bv605 (HECA-452)         CD3 PerCP-Cy5.5 (OKT3)         CD3 SV421 (UCHT1)         CD3 bv605 (SK7)         CD3 PE-Cy5.5 (UCHT1)         CD4 PE-594 (RPA-T4)         CD4 PE-Cy5 (RPA-T4)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend BD BioLegend BioLegend BioLegend BD eBioscience BioLegend BD eBioscience BioLegend BD	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA FITC (HECA-452)         CD1a FITC (HI149)         CD3 PerCP-Cy5.5 (OKT3)         CD3 Sev21 (UCHT1)         CD3 PE (HIT3a)         CD3 PE-Cy5.5 (UCHT1)         CD4 PE-594 (RPA-T4)         CD4 PE-594 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend BioLegend BioLegend BioLegend BD eBioscience BioLegend BioLegend BioLegend BioLegend BioLegend BioLegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 3005510 300526
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA bv605 (HECA-452)         CD1a FITC (H149)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PE (HIT3a)         CD3 PE-Cy5.5 (UCHT1)         CD4 PE-594 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend Biolegend Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD Biolegend Biolegend Biolegend BD	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong ™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA by605 (HECA-452)         CD1a FITC (H149)         CD3 PerCP-Cy5.5 (OKT3)         CD3 EV421 (UCHT1)         CD3 by605 (SK7)         CD3 PE (HIT3a)         CD3 PE (HT3a)         CD3 PE-Cy5.5 (UCH1)         CD4 PE-594 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Ve500 (RPA-T4)         CD5 PE (OKT8)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend BD eBioscience Biolegend BD eBioscience Biolegend Biolegend Biolegend BD eBioscience	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 34835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA bv605 (HECA-452)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PerCP-Cy5.5 (OKT3)         CD3 Ve21 (UCHT1)         CD3 bv605 (SK7)         CD3 PE-Cy5.5 (UCHT1)         CD4 PE-S94 (RPA-T4)         CD4 PE-Cy5 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD8 PE (OKT8)         CD8 Pacific Orange (3B5)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend BD eBioscience Biolegend Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD BD	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA FITC (HECA-452)         CD3 PerCP-Cy5.5 (OKT3)         CD3 SVe21 (UCHT1)         CD3 Ve21 (UCHT1)         CD3 PE (HIT3a)         CD3 PE-Cy5.5 (UCHT1)         CD4 FIE-Cy5 (RPA-T4)         CD4 PE-S94 (RPA-T4)         CD4 PE-Cy5 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD8 PE (OKT8)         CD8 PE (CKT8)         CD8 PE (CKT8)         CD8 by510 (RPA-T8)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend BioLegend BioLegend BioLegend BioLegend BioLegend BioLegend BioLegend BioLegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA FITC (HECA-452)         CD1a FITC (H149)         CD3 PerCP-0y5.5 (OKT3)         CD3 PerCP-0y5.5 (OKT3)         CD3 Pet (UCHT1)         CD3 PE (HIT3a)         CD3 PE (HIT3a)         CD3 PE (APA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD5 Peo(OKT8)         CD8 Peo(IT8)         CD8 bv510 (RPA-T8)         CD14 bv421 (M5E2)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong ™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA bv05 (HECA-452)         CD1a FITC (H149)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PerCP-Cy5.5 (OKT3)         CD3 bv605 (SK7)         CD3 PE (HIT3a)         CD3 PE-Cy5.5 (UCH1)         CD4 PE-594 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD8 PE (OKT8)         CD8 bv510 (RPA-T8)         CD14 bv421 (MEE2)         CD4 Sv510 (RPA-78)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend Biolegend Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 300434 34835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302608
ReagentCell Conditioning 1 (CC1)Eosin Y aqueous solutionHemalum solution acid acc. to MayerHuman Cytokeratin 5/6 (D5/16B4)ProLong TM Gold Antifade Mountant with DAPITissueTek O.C.T. CompoundultraView Universal DAB Detection kitAntibodiesReagentCLA FITC (HECA-452)CLA bv605 (HECA-452)CD3 PerCP-Cy5.5 (OKT3)CD3 SPerCP-Cy5.5 (OKT3)CD3 PetCP-Cy5.5 (UCHT1)CD4 PE-S94 (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD8 PE (OKT8)CD8 Pacific Orange (3B5)CD8 bv510 (RPA-T8)CD12 SPE-Cy7 (BC96)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend Biolegend Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302608 302612
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA bv605 (HECA-452)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PerCP-Cy5.5 (UCHT1)         CD4 PE-594 (RPA-T4)         CD4 PE-594 (RPA-T4)         CD4 PE-594 (RPA-T4)         CD4 PE-594 (RPA-T4)         CD4 PE-0y5 (RPA-T4)         CD5 PE-Cy5 (RPA-T8)         CD14 bv421 (M5E2)         CD25 PE-Cy5 (RD4)         CD25 PE-Cy5 (RD4)         CD4 PC-0y5 (RPA-T8)         CD14 bv421 (M5E2)         CD25 PE-Cy7 (BC96)         CD45 PerCP-Cy5.5 (H130)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302602 564105
ReagentCell Conditioning 1 (CC1)Eosin Y aqueous solutionHemalum solution acid acc. to MayerHuman Cytokeratin 5/6 (D5/16B4)ProLong™ Gold Antifade Mountant with DAPITissueTek O.C.T. CompoundultraView Universal DAB Detection kitAntibodiesReagentCLA FITC (HECA-452)CD1a FITC (HI149)CD3 PerCP-Cy5.5 (OKT3)CD3 PerCP-Cy5.5 (OKT3)CD3 PE (HIT3a)CD4 PE-Cy5 (UCHT1)CD4 PE-Cy5 (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD4 Alexa Fluor 700 (RPA-T4)CD4 Nexo (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD4 bv500 (RPA-T4)CD4 bv500 (RPA-T4)CD4 bv500 (RPA-T4)CD5 PE-Cy5CD14 bv421 (M5E2)CD25 PE-Cy6CD25 PE-Cy7 (BC96)CD45 PerCP-Cy5.5 (HI30)CD45 APC (HI30)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend BioLegend BioLegend BioLegend BioLegend BioLegend BioLegend Biolegend Biolegend Biolegend BD eBioscience BioLegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300550 300526 560768 12-0086-42 MHCD0830 301048 301830 302608 302612 564105 17-0459-42
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA bv605 (HECA-452)         CD1a FITC (H149)         CD3 Ve605 (SK7)         CD3 Ve605 (SK7)         CD3 Ve605 (SK7)         CD3 PE (HIT3a)         CD3 PE-Cy5.5 (UCHT1)         CD4 PE-594 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD4 Alexa Fluor 700 (RPA-T4)         CD8 ve601 (RPA-T8)         CD14 bv501 (RPA-T8)         CD14 bv421 (M5E2)         CD25 PE-Cy5         CD25 PE-Cy5         CD25 PE-Cy5 (H30)         CD4 Sev76.5 (H30)         CD4 Sev785 (H30)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend Biolegend Biolegend BD eBioscience Biolegend Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend BD eBioscience Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 Catalog number 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302608 302612 564105 17-0459-42 304048
ReagentCell Conditioning 1 (CC1)Eosin Y aqueous solutionHemalum solution acid acc. to MayerHuman Cytokeratin 5/6 (D5/16B4)ProLong TM Gold Antifade Mountant with DAPITissueTek O.C.T. CompoundultraView Universal DAB Detection kitAntibodiesReagentCLA FITC (HECA-452)CLA bv605 (HECA-452)CD3 PerCP-Cy5.5 (OKT3)CD3 PerCP-Cy5.5 (OKT3)CD3 PerCP-Cy5.5 (UCHT1)CD4 PE-S94 (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD4 PE-Cy6 (RPA-T4)CD4 PE-Cy6 (RPA-T4)CD4 PE-Cy5 (RPA-T4)CD5 PE-Cy7 (BC96)CD5 PE-Cy7 (BC96)CD45 PerCP-Cy5.5 (HI30)CD45 RA PE-e610 (HI100)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend Bio	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 Catalog number 321306 563960 300104 45-0037-42 300434 300514 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302608 302612 564105 17-0459-42 304048 61-0458-42
Reagent           Cell Conditioning 1 (CC1)           Eosin Y aqueous solution           Hemalum solution acid acc. to Mayer           Human Cytokeratin 5/6 (D5/16B4)           ProLong™ Gold Antifade Mountant with DAPI           TissueTek O.C.T. Compound           ultraView Universal DAB Detection kit           Antibodies           Reagent           CLA FITC (HECA-452)           CLA bv605 (HECA-452)           CD3 PerCP-Cy5.5 (OKT3)           CD3 PerCP-Cy5.5 (OKT3)           CD3 PerCP-Cy5.5 (UCHT1)           CD4 PE-594 (RPA-T4)           CD4 PE-595 (UCHT1)           CD4 PE-594 (RPA-T4)           CD4 PE-Cy5 (RPA-T8)           CD5 PE-Cy7           CD5 PE-Cy7 (BC96)           CD45 PerC-Cy5.5 (H130)           CD45 RAPE-c610 (H1100)           CD45 RAPE-CP-Cy5.5 (H1100)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend BioLegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 301048 301830 302612 564105 17-0459-42 304048 61-0458-42 304122
Reagent         Cell Conditioning 1 (CC1)         Eosin Y aqueous solution         Hemalum solution acid acc. to Mayer         Human Cytokeratin 5/6 (D5/16B4)         ProLong™ Gold Antifade Mountant with DAPI         TissueTek O.C.T. Compound         ultraView Universal DAB Detection kit         Antibodies         Reagent         CLA FITC (HECA-452)         CLA FITC (HECA-452)         CD1a FITC (H149)         CD3 PerCP-Cy5.5 (OKT3)         CD3 PerCP-Cy5.5 (UCHT1)         CD4 Set (UCHT1)         CD3 PE (HIT3a)         CD3 PE (HIT3a)         CD3 PE (APA-T4)         CD4 PE-594 (RPA-T4)         CD4 PE-Cy5 (RPA-T4)         CD4 PE-Cy5 (RPA-T4)         CD4 Vos00 (RPA-T4)         CD4 PE (OKT8)         CD8 PerCit Orange (3B5)         CD8 PerCit Orange (3B5)         CD5 PE-Cy5         CD4 SU (RPA-T8)         CD14 bv421 (M5E2)         CD25 PE-Cy5         CD45 PerCP-Cy5.5 (H130)         CD45 SV785 (H130)         CD45 SV785 (H130)         CD45 RAPerCP-Cy5.5 (H1100)         CD45 RAPerCP-Cy5.5 (H1100)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302608 302612 564105 17-0459-42 304048 61-0458-42 304122 304120
ReagentCell Conditioning 1 (CC1)Eosin Y aqueous solutionHemalum solution acid acc. to MayerHuman Cytokeratin 5/6 (D5/16B4)ProLong ™ Gold Antifade Mountant with DAPITissueTek O.C.T. CompoundultraView Universal DAB Detection kitAntibodiesReagentCLA FITC (HECA-452)CD1a FITC (H149)CD3 PerCP-Cy5.5 (OKT3)CD3 PerCP-Cy5.5 (OKT3)CD3 PerCP-Cy5.5 (OKT3)CD3 PE (HIT3a)CD3 PE (HIT3a)CD3 PE (VPA-T4)CD4 Alexa Fluor 700 (RPA-T4)CD4 Alexa Fluor 700 (RPA-T4)CD4 bv500 (RPA-T8)CD14 bv421 (M5E2)CD25 PE-Cy5CD25 PE-Cy6CD25 PE-Cy7 (BC96)CD45 PerCP-Cy5.5 (H130)CD45 RA PE-e610 (H1100)CD45RA PIE-e610 (H1100) <tr< td=""><td>Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD BioLegend</td><td>950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500</td></tr<>	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD BioLegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500
Reagent           Cell Conditioning 1 (CC1)           Eosin Y aqueous solution           Hemalum solution acid acc. to Mayer           Human Cytokeratin 5/6 (D5/16B4)           ProLong™ Gold Antifade Mountant with DAPI           TissueTek O.C.T. Compound           ultraView Universal DAB Detection kit           Antibodies           Reagent           CLA FITC (HECA-452)           CLA FITC (HECA-452)           CD1a FITC (H149)           CD3 PerCP-Cy5.5 (OKT3)           CD3 Ved1 (UCHT1)           CD3 bed05 (SK7)           CD3 PE (HIT3a)           CD3 PE-Cy5.5 (UCHT1)           CD4 PE-594 (RPA-T4)           CD4 PE-Cy5 (RPA-T4)           CD4 PE-Cy5 (RPA-T4)           CD4 PE-Cy5 (RPA-T4)           CD4 Alexa Fluor 700 (RPA-T4)           CD4 PE-Cy5 (RPA-T4)           CD4 PE-Cy5 (RPA-T4)           CD4 PE-Cy5 (RPA-T4)           CD4 bv500 (RPA-T4)           CD8 Pacific Orange (3B5)           CD8 bv510 (RPA-T8)           CD14 bv421 (M5E2)           CD25 PE-Cy5           CD25 PE-Cy6           CD25 PE-Cy5 (H130)           CD45 PCP-Cy5.5 (H130)           CD45 RAPE(RD-Cy5.5 (H1100)           CD45 RAPE-e610 (H11	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 <b>Catalog number</b> 321306 563960 300104 45-0037-42 300434 344835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302608 302612 564105 17-0459-42 304048 61-0458-42 304122 304120
ReagentCell Conditioning 1 (CC1)Eosin Y aqueous solutionHemalum solution acid acc. to MayerHuman Cytokeratin 5/6 (D5/16B4)ProLong $^{TM}$ Gold Antifade Mountant with DAPITissueTek O.C.T. CompoundultraView Universal DAB Detection kitAntibodiesReagentCLA FITC (HECA-452)CLA bv605 (HECA-452)CD3 PerCP-Cy5.5 (OKT3)CD3 PerCP-Cy5.5 (OKT3)CD3 PerCP-Cy5.5 (OKT3)CD3 PetCP-Cy5.5 (UCHT1)CD4 PE-S94 (RPA-T4)CD4 PE-Cy6 (RPA-T4)CD4 PE-Cy6 (RPA-T4)CD4 Alexa Fluor 700 (RPA-T4)CD4 PE-Cy5CD5 PE (OKT8)CD5 PE (OKT8)CD5 PE-Cy5.5 (HI30)CD4 SPC-Cy5.5 (HI30)CD4 SPC-Cy5.5 (HI30)CD4 SPC-Cy5.5 (HI100)CD4 SRA Pe-ce10 (H1100)CD4SRA Pe-Cy5.5 (HI100)CD4SRA Alexa Fluor 700 (H1100)CD4SRA Alexa Fluor 700 (H1100)CD5 PE-Cy5CD25 PE-Cy5CD25 PE-Cy5 (CD25 PE-Cy5.5 (HI30)CD4 SPCP-Cy5.5 (HI30)CD4SRA PE-e610 (H1100)CD4SRA PE-e70 (C034E3)	Roche Sigma Carl Rorth Roche Invitrogen Sakura Roche Biolegend BD Biolegend BioLegend	950-124 HT110232 T865.1 790-4554 P36931 TTEK 760-500 Catalog number 321306 563960 300104 45-0037-42 300434 300434 34835 561803 15-0038-42 300548 300510 300526 560768 12-0086-42 MHCD0830 301048 301830 302608 302612 564105 17-0459-42 304048 61-0458-42 304122 304120 12-0869-41 353418

Foxp3 eFluor450 (PCH101)	eBioscience	50-4776-41
GM-CSF bv421 (BVD2-21C11)	BD	562930
HLA-DR AF700 (L243)	BioLegend	307626
HLA-DR eFluor 780 (LN3)	eBioscience	47-9956-42
IFNg PE-Cy7 (B27)	BioLegend	506518
IFN-g BV605 (4S.B3)	BD	563731
IL-2 PE (MQ1-17H12)	eBioscience	12-7029-42
IL17A APC (BL168)	BioLegend	512334
IL-17A PerCP-Cy5.5 (eBio64DEC17)	eBioscience	45-7179-42
IL-13 PE (JES10-5A2)	BD	554571
IL-22 PE-Cy7 (22URTI)	eBioscience	25-7229-42
ki67 bv605 (ki67)	BioLegend	350521
ki-67 PE-Cy7 (SolA15)	eBioscience	25-5698-82
TNFa FITC (Mab11)	BioLegend	502915
TCRgd PerCP-eFluor710 (B1.1)	eBioscience	46-9959
Fixable Viability Dye eFluor™ 780	eBioscience	65-0865-14
Fixable Viability Dye eFluor™ 520	eBioscience	65-0867-14
eBioscience™ Fixable Viability Dye eFluor™ 506	eBioscience	65-0866-14
IF primary antibody: rabbit anti-human NC-1 domain of type VII collagen (LH7.2)	kindly provided by Dr. Alexander Nyström, University of Freiburg, Germany	
IF secondary antibody: goat anti-rabbit A488	ThermoFisher	A11008
mLy6G (Gr-1) InVivoMab RB6-8C5	BioXcell	BE0075
Cell Proliferation Dye eFluor™ 450	ThermoFisher	65-0842-85